Lola Rahib, PhD Lead Scientist in Pancreatic Cancer at Cancer Commons
-
June 12, 2021
Navigating Pancreatic Cancer: Apps at Your Fingertips Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: Learn how patients and caregivers can utilize cancer apps to find resources, track symptoms, contribute to research, and more.
.
-
June 12, 2021
Drafting Your Health Care Team Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: Patients need different types of healthcare professionals when diagnosed with pancreatic cancer. A multidisciplinary team of experts are care professionals that work together and have different roles in helping patients with pancreatic cancer.
.
-
June 12, 2021
Managing the Side Effects of Pancreatic Cancer Treatment Bookmark
Lola Rahib, PhDArticle from Let’s Win! Pancreatic Cancer: Learn about the side effects from pancreatic cancer treatment and how they can be managed by physicians and patients.
.
-
June 29, 2020
Cancer Screening Programs Influence Incidence and Causes of Cancer Deaths Bookmark
Lola Rahib, PhDArticle from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.
In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.
Go to full article published by ASCO Daily News.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 20, 2020
How the Coronavirus Pandemic Impacts Cancer Care: Our Survey Results
With: Lola Rahib, PhDThe ongoing COVID-19 pandemic presents unprecedented challenges to cancer patients. Many have experienced changes to their care, and some face increased risk of infection or worse prognosis if they are infected. In partnership with the company xCures, Cancer Commons is studying how COVID-19 impacts cancer patients. Here, our Curious Dr. George asks Cancer Commons Director of Scientific and Clinical Affairs Lola Rahib, PhD, about… Read more »
-
May 12, 2020
Pancreatic Cancer Survival Rates: What Do They Really Mean?
Lola Rahib, PhDThe American Cancer Society estimates that in 2020, 57,600 people in the U.S. will be diagnosed with pancreatic cancer and 47,050 will die from the disease. But not everyone’s pancreatic cancer is the same. Understanding what survival rates mean—and which factors can impact them—could help you navigate your or your loved one’s disease. What is the five-year relative survival rate for pancreatic cancer? In… Read more »
-
January 10, 2020
Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer Patients
Lola Rahib, PhDIn collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for pancreatic cancer patients at a conference in San Diego, CA, today. The “Special Conference on Advancing Precision Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies” is hosted by the… Read more »
-
August 5, 2019
Navigating Pancreatic Cancer—The Basics
With: Lola Rahib, PhDA Q&A with Lola Rahib, PhD, Lead Scientist, Pancreas Cancer, at Cancer Commons, Los Altos, CA; lola.rahib@cancercommons.org Q: Navigating a pancreatic cancer diagnosis can be overwhelming and confusing for patients and their loved ones. How can patients and their caregivers ensure having the knowledge, support, and plan they need to be able to navigate treatment options and other aspects of the disease? A: Patients… Read more »